BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 15947768)

  • 1. Incidence of cerebral embolism after cardioversion of atrial fibrillation: a prospective study with transesophageal echocardiography and cerebral magnetic resonance imaging.
    Bernhardt P; Schmidt H; Hammerstingl C; Lüderitz B; Omran H
    J Am Soc Echocardiogr; 2005 Jun; 18(6):649-53. PubMed ID: 15947768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients at high risk with atrial fibrillation: a prospective and serial follow-up during 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging.
    Bernhardt P; Schmidt H; Hammerstingl C; Lüderitz B; Omran H
    J Am Soc Echocardiogr; 2005 Sep; 18(9):919-24. PubMed ID: 16153514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term fate of left atrial thrombi and incidence of cerebral embolism under continuous anticoagulation therapy].
    Strach K; Meyer C; Hackenbroch M; Tiemann K; Haase J; Pizulli L; Omran H; Schild H; Sommer T
    Rofo; 2005 Dec; 177(12):1706-12. PubMed ID: 16333795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion.
    Bechtold H; Gunzenhauser D; Sawitzki H; Fung S; Janssen D
    Z Kardiol; 2003 Jul; 92(7):532-9. PubMed ID: 12883837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial.
    Klein AL; Grimm RA; Jasper SE; Murray RD; Apperson-Hansen C; Lieber EA; Black IW; Davidoff R; Erbel R; Halperin JL; Orsinelli DA; Porter TR; Stoddard MF;
    Am Heart J; 2006 Feb; 151(2):380-9. PubMed ID: 16442904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delaying cardioversion following 4-week anticoagulation in case of persistent atrial fibrillation after a transcatheter ablation procedure to reduce silent cerebral thromboembolism: a single-center pilot study.
    Pianelli M; Scaglione M; Anselmino M; Caponi D; Garcia P; Cesarani F; Toso E; Raimondo C; Halimi F; Leclercq JF; Gaita F
    J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):785-9. PubMed ID: 21941200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atrial fibrillation - patients at high risk for cerebral embolism.
    Bernhardt P; Schmidt H; Sommer T; Lüderitz B; Omran H
    Clin Res Cardiol; 2006 Mar; 95(3):148-53. PubMed ID: 16598527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of transesophageal echocardiography guided cardioversion in patients with atrial fibrillation, previous left atrial thrombus and effective anticoagulation.
    Saeed M; Rahman A; Afzal A; Agoston I; Jammula P; Birnbaum Y; Ware DL; Uretsky BF; Schwarz ER; Rosanio S
    Int J Cardiol; 2006 Nov; 113(3):401-5. PubMed ID: 16822564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi.
    Manning WJ; Silverman DI; Gordon SP; Krumholz HM; Douglas PS
    N Engl J Med; 1993 Mar; 328(11):750-5. PubMed ID: 8437595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardioversion in patients with left ventricular thrombus is not associated with increased thromboembolic risk.
    Bangalore S; Petre L; Herweg B; Sichrovsky T; Vragel S; Steinberg JS; Chaudhry FA
    J Am Soc Echocardiogr; 2006 Apr; 19(4):438-40. PubMed ID: 16581484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation: ACUTE trial update.
    Asher CR; Klein AL;
    Card Electrophysiol Rev; 2003 Dec; 7(4):387-91. PubMed ID: 15071261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health status outcomes after cardioversion for atrial fibrillation: results from the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Trial.
    Elliott DJ; Zhao L; Jasper SE; Lieber EA; Klein AL; Weintraub WS
    Am Heart J; 2008 Aug; 156(2):374.e1-6. PubMed ID: 18657673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of spontaneous echocontrast, 'sludge' and thrombi before cardioversion in patients with atrial fibrillation: new insights into the role of transesophageal echocardiography.
    Maltagliati A; Galli CA; Tamborini G; Celeste F; Muratori M; Pepi M
    J Cardiovasc Med (Hagerstown); 2009 Jul; 10(7):523-8. PubMed ID: 19474574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study).
    Sorino M; Colonna P; De Luca L; Carerj S; Oliva E; De Tommasi SM; Conti U; Iacopi F; D'Agostino C; D'Amato N; Pettinati G; Montericcio V; Cualbu A; De Luca I
    J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1034-42. PubMed ID: 18163016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging.
    Bernhardt P; Schmidt H; Hammerstingl C; Lüderitz B; Omran H
    J Am Coll Cardiol; 2005 Jun; 45(11):1807-12. PubMed ID: 15936610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Schmidt-Lucke C; Paar WD; Stellbrink C; Nixdorff U; Hofmann T; Meurer J; Grewe R; Daniel WG; Hanrath P; Mügge A; Klein HU; Schmidt-Lucke JA
    Thromb Res; 2007; 119(1):27-34. PubMed ID: 16443257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-limited bursts of atrial fibrillation following successful cardioversion.
    Nergårdh AK; Rosenqvist M; Frick M
    Int J Cardiol; 2007 Jun; 119(1):95-100. PubMed ID: 17064786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of silent microembolism by magnetic resonance imaging after cardioversion in atrial fibrillation.
    Vázquez M; Santos E; Rodriguez I; Pato A; Vilar M; Arias JC; Fernández R; Costas I; Ghioldi A; Sanmartin M; Tardáguila F
    Rev Esp Cardiol (Engl Ed); 2012 Feb; 65(2):139-42. PubMed ID: 22153725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymptomatic cerebral lesions during pulmonary vein isolation under uninterrupted oral anticoagulation.
    Martinek M; Sigmund E; Lemes C; Derndorfer M; Aichinger J; Winter S; Jauker W; Gschwendtner M; Nesser HJ; Pürerfellner H
    Europace; 2013 Mar; 15(3):325-31. PubMed ID: 23097222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.